Promising Nanotechnology Stocks To Follow Today – May 16th

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of companies involved in the research, development, or commercialization of materials and devices engineered at the nanoscale (typically under 100 nanometers). Investors buy these equities to gain exposure to potential breakthroughs in fields such as medicine, electronics, energy, and materials science that leverage nanoscale properties. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ OSIS traded up $2.34 on Friday, reaching $230.32. 69,239 shares of the company were exchanged, compared to its average volume of 191,738. The business’s fifty day moving average price is $198.80 and its 200 day moving average price is $184.73. The stock has a market capitalization of $3.87 billion, a P/E ratio of 29.58, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. OSI Systems has a fifty-two week low of $129.18 and a fifty-two week high of $233.80.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NASDAQ:NVEC traded up $0.25 on Friday, reaching $71.28. The company’s stock had a trading volume of 11,172 shares, compared to its average volume of 22,436. NVE has a 12-month low of $51.50 and a 12-month high of $89.98. The firm has a market cap of $344.78 million, a price-to-earnings ratio of 22.83 and a beta of 1.09. The stock has a 50 day moving average price of $62.01 and a 200 day moving average price of $71.39.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of BDRX stock traded down $0.01 on Friday, hitting $1.29. The stock had a trading volume of 32,206 shares, compared to its average volume of 592,522. Biodexa Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $74.00. The company’s 50 day moving average price is $1.56 and its 200-day moving average price is $3.45.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ CLNN traded up $0.01 during trading hours on Friday, hitting $2.59. 15,651 shares of the company were exchanged, compared to its average volume of 79,322. The company has a 50 day moving average of $3.22 and a two-hundred day moving average of $4.25. Clene has a 52-week low of $2.52 and a 52-week high of $9.20. The firm has a market cap of $23.27 million, a price-to-earnings ratio of -0.49 and a beta of 0.46.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ VRPX traded down $0.01 during trading hours on Friday, hitting $0.23. 11,005 shares of the company were exchanged, compared to its average volume of 201,169. The company has a 50 day moving average of $1.06 and a two-hundred day moving average of $6.83. Virpax Pharmaceuticals has a 52-week low of $0.13 and a 52-week high of $84.75.